To receive your instant certificate, you must "Sign In" or "Sign Up" in the top right corner.
FORMAT: Complimentary CME Monograph
MAXIMUM CREDITS: Earn Up to 1.0 AMA PRA Category 1 Credit ™
Release Date: December 23, 2019
Expiration Date: December 23, 2020
CLICK HERE TO PROCEED TO PROGRAM
Sleep disturbances are common among older adults, with an even higher prevalence among people with neurodegenerative conditions. As many as 70% of older adults with dementia have sleep disturbance compared with approximately half of older adults without dementia. For persons with Alzheimer disease (AD), sleep problems predict both institutionalization and mortality. The driver of institutionalization is likely multifactorial, stemming from the increased burden placed on caregivers when sleep is disrupted and the direct effect of disrupted sleep in driving AD progression through inflammation and increased β-amyloid accumulation. Early and appropriate screening for sleep disturbances in general, and insomnia in particular, among this patient cohort is critical. Management of insomnia in the setting of AD requires a holistic and multifaceted approach, considering both nonpharmacologic interventions and, when clinically indicated, pharmacologic therapy . Although most hypnotics currently available for managing insomnia lack specific efficacy and safety data for AD, newer treatments—specifically targeting unique brain sites mediating sleep and wakefulness—may have a role, along with additional intervention such as bright light therapy. The desired result of this activity is for neurologists to evaluate evidence-based and safe treatment strategies for managing insomnia in the setting of AD.
Jointly provided by Postgraduate Institute for Medicine ( www.pimed.com) and MedEdicus LLC
This activity is supported by an independent educational grant from Merck & Co., Inc.
PROCEED TO PROGRAM